Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Drug's journey through the body tested in liver health study

NCT ID NCT07324616

First seen Jan 09, 2026 · Last updated May 22, 2026 · Updated 17 times

Summary

This early-stage study looks at how a single dose of the experimental drug EDG-7500 stays in the blood of people with mild or moderate liver problems compared to those with healthy livers. About 32 adults will take one pill, and researchers will measure drug levels and check for side effects. The goal is to learn how liver function affects the drug, not to treat any condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT (HI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Orlando Clinical Research Center

    RECRUITING

    Orlando, Florida, 32809, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The University of Miami Division of Clinical Pharmacology

    RECRUITING

    Miami, Florida, 33136, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.